COMPOUND DEEP DIVES · RESEARCH PROTOCOLS & STACKS
Conventional wisdom says that losing fat and gaining lean mass simultaneously is physiologically impossible — that the body must choose between a caloric surplus for anabolism or a deficit for lipolysis. The preclinical and clinical literature on growth hormone axis modulation and mitochondrial signalling suggests the picture is more nuanced than that.
Three research compounds have each accumulated independent mechanistic data relevant to body recomposition: CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog that sustains GH and IGF-I elevation for days from a single injection; Tesamorelin, a synthetic GHRH analog with the most robust clinical dataset for visceral adipose tissue (VAT) reduction of any compound in this category; and MOTS-c, a 16-amino-acid mitochondrial-encoded signalling molecule that activates AMPK in skeletal muscle independently of the GH axis entirely.
What makes the Recomp Stack conceptually interesting isn’t that each of these compounds shares a mechanism — it’s that they operate on different axes with minimal mechanistic overlap. CJC-1295 and Tesamorelin both engage pituitary GHRH receptors but with distinct half-lives and dosing profiles. MOTS-c bypasses the pituitary entirely, targeting skeletal muscle metabolism via the mitochondria-AMPK-nucleus axis.
The caveat is upfront: no peer-reviewed study has examined these three compounds in combination. The synergy is theoretical. What the data can support is the individual mechanistic logic for each compound in a recomposition context — and that’s what this post examines, rigorously.
Growth hormone exerts its body composition effects through two primary mechanisms: direct lipolytic action on adipose tissue (particularly visceral fat, which expresses higher GH receptor density than subcutaneous depots) and indirect anabolic effects mediated by IGF-I produced primarily in the liver. The problem with exogenous GH administration is the complete suppression of endogenous pulsatile secretion — a physiological rhythm that matters for long-term axis health. GHRH analogs like CJC-1295 and Tesamorelin circumvent this by stimulating the pituitary to release GH endogenously, preserving — and in CJC-1295’s case explicitly confirmed to preserve — natural pulse frequency.
CJC-1295 is a tetrasubstituted GHRH(1-29) derivative with a maleimidopropionamide group enabling covalent binding to Cys34 of endogenous serum albumin. This albumin bioconjugation is the key engineering insight: it dramatically extends plasma half-life from the ~7-minute half-life of native GHRH to 5.8–8.1 days (Teichman SL et al., 2006, PMID: 16352683). In Sprague-Dawley rat models, Jette L et al. confirmed the albumin-bound species persists for >72 hours post-injection and produces a 4-fold greater GH area under the curve versus unmodified hGRF(1-29) (Jette L et al., 2005, PMID: 15817669). In GHRH-knockout mice treated daily with CJC-1295, body weight, body length, and lean mass were fully normalised to wild-type levels within 5 weeks of daily administration (Alba M et al., 2006, PMID: 16822960).
Tesamorelin is a synthetic GHRH(1-44) analog — retaining more of the native sequence than CJC-1295 — with a trans-3-hexenoic acid modification at its N-terminus that stabilises it against dipeptidyl peptidase IV (DPP-IV) cleavage. Unlike CJC-1295, Tesamorelin has an established Phase III clinical dataset across HIV-associated lipodystrophy populations, including five RCTs that form the basis of a 2026 meta-analysis (Badran AS et al., 2026, PMID: 41545261) and a separate 12-month RCT in 60 abdominally obese non-HIV subjects (Makimura H et al., 2012, PMID: 23015655).
MOTS-c is encoded in the mitochondrial 12S ribosomal RNA gene — an unusual origin for a signalling molecule. Its primary site of action is skeletal muscle, where it inhibits the folate cycle and de novo purine biosynthesis, leading to AICAR accumulation and AMPK activation. The foundational mouse work by Lee C et al. in diet-induced obese and aged animals established its role as a functional exercise mimetic (Lee C et al., 2015, PMID: 25738459). Subsequent research confirmed a secondary nucleus-translocation mechanism under metabolic stress, where MOTS-c directly reprograms gene expression networks via antioxidant response element (ARE) binding (Kim KH et al., 2018, PMID: 29983246).
In two randomised, placebo-controlled, double-blind Phase I/II trials in healthy adults aged 21–61, a single subcutaneous injection of CJC-1295 produced dose-dependent increases in mean plasma GH of 2- to 10-fold, sustained for a minimum of 6 days, with IGF-I elevations of 1.5- to 3-fold lasting 9–11 days. After multiple weekly doses, mean IGF-I levels remained above baseline for up to 28 days. No serious adverse events were reported at doses of 30–60 µg/kg (Teichman SL et al., 2006, PMID: 16352683).
Critically, Ionescu M et al. in a separate healthy male cohort aged 20–40 demonstrated that CJC-1295 at 60–90 µg/kg increased trough (basal) GH levels by 7.5-fold (P < 0.0001) and raised mean GH levels by 46% (P < 0.01) while preserving natural pulsatile GH secretory frequency. IGF-I rose by 45% (P < 0.001). The mechanistic distinction here is important: it was trough GH elevation — not pulse frequency — that drove IGF-I increases, distinguishing CJC-1295 from conventional short-acting GHRH analogs (Ionescu M et al., 2006, PMID: 17018654).
The mouse knockout model adds a further mechanistic layer: CJC-1295 not only drives GH release but appears to upregulate somatotroph proliferation, with increased total pituitary GH mRNA observed — suggesting the compound amplifies endogenous GH secretory capacity rather than simply substituting for absent GHRH (Alba M et al., 2006, PMID: 16822960).
Tesamorelin’s clinical dataset is the strongest in this stack. The 2026 meta-analysis of five RCTs (Badran AS et al., 2026, PMID: 41545261) found Tesamorelin at 2 mg/day produced:
The visceral selectivity is mechanistically explained by visceral adipose tissue’s higher density of GH receptors compared to subcutaneous depots, making it disproportionately responsive to GH-driven lipolysis. The pooled Phase III data from Falutz J et al. — 806 subjects, 2:1 randomisation to Tesamorelin 2 mg/day vs. placebo — confirmed a −15.4% VAT reduction (−24 ± 41 cm²) at 26 weeks versus +2 cm² in placebo (P < 0.001), with reductions maintained through 52 weeks at −17.5% (Falutz J et al., 2010, PMID: 20554713). Triglycerides declined by −48 mg/dL (P < 0.001). IGF-I rose by 108 ± 112 ng/mL (P < 0.001).
In the non-HIV obese population — a more relevant reference cohort for most self-optimisers — Makimura H et al.’s 12-month RCT (n=60) showed Tesamorelin selectively reduced VAT by 35 cm² (95% CI −58 to −12; P = 0.003), improved carotid intima-media thickness by −0.04 mm (P = 0.02), reduced CRP (P = 0.04), and triglycerides by −37 mg/dL (P = 0.02) — without altering subcutaneous fat, fasting glucose, 2-hour glucose, or HbA1c (Makimura H et al., 2012, PMID: 23015655).
Tesamorelin’s hepatic effects extend beyond fat reduction. RCT-embedded transcriptomic analysis of paired liver biopsies from a 12-month trial showed Tesamorelin upregulated hepatic oxidative phosphorylation gene sets and downregulated inflammatory and fibrogenic pathways including TGF-β1, VEGFA, and CSF1 (Fourman LT et al., 2020, PMID: 32701508). This is not just a fat-mobilising compound — it is actively reprogramming hepatic metabolism at the transcriptional level.
Stanley TL et al.’s responder analysis further refines the picture: in the 402-subject Phase III cohort, subjects achieving ≥8% VAT reduction showed significantly greater triglyceride reductions (−0.6 vs. −0.1 mmol/L; P = 0.005) and attenuated fasting glucose changes (1 vs. 5 mg/dL; P = 0.01) compared to non-responders, with significant adiponectin improvements — demonstrating that the magnitude of visceral fat reduction, not Tesamorelin exposure per se, predicts metabolic benefit (Stanley TL et al., 2012, PMID: 22495074).
MOTS-c operates on an entirely different axis. Encoded in the mitochondrial genome rather than the nuclear genome, this 16-amino-acid signalling molecule targets skeletal muscle metabolism through the folate cycle inhibition → AICAR accumulation → AMPK activation pathway. In diet-induced obese mice, MOTS-c administration prevented obesity and insulin resistance. In aged mice, it reversed age-dependent insulin resistance. These effects required AMPK activation and increased fatty acid β-oxidation (Lee C et al., 2015, PMID: 25738459).
The 2019 metabolomics study by Kim SJ et al. in DIO mice treated with MOTS-c identified reductions in three metabolic pathways elevated in obese/T2D states: sphingolipid metabolism, monoacylglycerol metabolism, and dicarboxylate metabolism. MOTS-c increased β-oxidation and improved insulin sensitivity, preventing ectopic fat accumulation (Kim SJ et al., 2019, PMID: 31293078).
The nuclear translocation finding from Kim KH et al. adds a second mechanistic tier: under metabolic stress (glucose restriction), MOTS-c translocates from mitochondria to the nucleus in an AMPK-dependent manner, where it binds ARE-bearing gene networks and interacts with the stress-responsive transcription factor NRF2, actively reprogramming nuclear gene expression (Kim KH et al., 2018, PMID: 29983246). This is not a peripheral metabolic effector — it is a retrograde mitochondrial signal that reshapes how the nucleus responds to energetic stress.
Circulating MOTS-c levels decline with age across human populations. A 2022 review (Mohtashami Z et al., 2022, PMID: 36233287) identifies preclinical evidence for MOTS-c benefit in age-associated conditions including type 2 diabetes, cardiovascular dysfunction, postmenopausal obesity, and loss of skeletal muscle homeostasis, with the folate-AICAR-AMPK pathway as the primary mechanistic axis.
In the first direct human correlational evidence, Domin R et al. found that resting serum MOTS-c concentration in 20 physically active adults (median age 30) positively correlated with average jump power, average and maximal force, overall muscle mass, and leg muscle mass — but not body fat percentage or peak VO₂ (Domin R et al., 2023, PMID: 37834399). The absence of a VO₂ correlation is meaningful: MOTS-c’s role appears preferentially linked to muscle mass and explosive strength, not aerobic capacity.
Table 1: GH Axis Compounds — Key Outcomes by Study
| Compound | Study Type | Key Outcome | Citation |
|---|---|---|---|
| CJC-1295 | Phase I/II RCT, healthy adults (n=not specified per cohort) | 2–10× GH elevation sustained ≥6 days; IGF-I +1.5–3× for 9–11 days; half-life 5.8–8.1 days | Teichman SL et al., 2006, PMID: 16352683 |
| CJC-1295 | Phase I/II RCT, healthy men 20–40 | Trough GH +7.5× (P < 0.0001); mean GH +46% (P < 0.01); IGF-I +45% (P < 0.001); pulsatile frequency preserved | Ionescu M et al., 2006, PMID: 17018654 |
| CJC-1295 | GHRH-KO mouse, 5 weeks daily | Full normalisation of body weight, body length, lean mass, and femur/tibia length vs. wild-type | Alba M et al., 2006, PMID: 16822960 |
| Tesamorelin | Meta-analysis of 5 RCTs (HIV cohorts) | VAT −27.71 cm²; lean mass +1.42 kg; trunk fat −1.18 kg; hepatic fat −4.28%; no glucose perturbation | Badran AS et al., 2026, PMID: 41545261 |
| Tesamorelin | Phase III pooled RCT (n=806) | VAT −15.4% at 26 weeks; triglycerides −48 mg/dL; IGF-I +108 ng/mL; maintained at 52 weeks | Falutz J et al., 2010, PMID: 20554713 |
| Tesamorelin | RCT, abdominally obese non-HIV (n=60), 12 months | VAT −35 cm² (P = 0.003); triglycerides −37 mg/dL; CIMT −0.04 mm; no change in subcutaneous fat | Makimura H et al., 2012, PMID: 23015655 |
Table 2: MOTS-c — Mechanistic and Observational Evidence
| Compound | Study Type | Key Outcome | Citation |
|---|---|---|---|
| MOTS-c | Mouse model (DIO + aged mice) | Prevented obesity; reversed age-dependent insulin resistance; AMPK activation via folate cycle inhibition | Lee C et al., 2015, PMID: 25738459 |
| MOTS-c | In vitro, metabolic stress conditions | Nuclear translocation (AMPK-dependent); ARE/NRF2 gene network regulation; mitonuclear retrograde signalling | Kim KH et al., 2018, PMID: 29983246 |
| MOTS-c | Mouse metabolomics (DIO model) | Reduced sphingolipid, monoacylglycerol, dicarboxylate pathways; increased β-oxidation; improved insulin sensitivity | Kim SJ et al., 2019, PMID: 31293078 |
| MOTS-c | Human correlational (n=20 physically active adults) | Serum MOTS-c correlated with leg muscle mass, jump power, and maximal force — not VO₂ or body fat % | Domin R et al., 2023, PMID: 37834399 |
| MOTS-c | Systematic review, human aging data | Circulating MOTS-c declines with age; preclinical evidence for benefit in T2D, postmenopausal obesity, sarcopenia | Mohtashami Z et al., 2022, PMID: 36233287 |
The mechanistic logic for the Recomp Stack has genuine scientific grounding. CJC-1295 and Tesamorelin both amplify endogenous GH secretion via pituitary GHRH receptor agonism, driving visceral lipolysis and IGF-I-mediated lean mass preservation. MOTS-c independently activates the AMPK pathway in skeletal muscle, enhancing fatty acid oxidation and improving insulin sensitivity through a mitochondria-to-nucleus signalling axis that the GH compounds do not touch. On paper, the axes are complementary without obvious redundancy. But the limitations are substantial and must be named explicitly.
Limitation 1: Tesamorelin’s clinical database is cohort-specific. Every Phase II and Phase III trial was conducted in HIV-positive subjects with ART-induced lipodystrophy — a metabolic state characterised by exaggerated VAT accumulation, dyslipidaemia, and disrupted GH pulsatility that does not map cleanly onto healthy, non-lipodystrophic populations. The single non-HIV trial (Makimura H et al., 2012, PMID: 23015655) used a sample of 60 abdominally obese adults with documented reduced GH secretion — again, not the average self-optimiser. Whether Tesamorelin produces meaningful VAT reduction in individuals without lipodystrophy and with normal GH secretion at baseline remains an open question that no published RCT has addressed.
Limitation 2: CJC-1295 has no long-term body composition endpoint data. The human pharmacokinetic and pharmacodynamic data from Teichman SL et al. and Ionescu M et al. establishes clearly that CJC-1295 produces sustained GH and IGF-I elevation in healthy adults. What it does not establish is whether this GH/IGF-I elevation translates to measurable fat mass reduction or lean mass accrual over weeks or months — because no clinical trial measuring body composition outcomes with CJC-1295 as sole intervention has been published. The mouse knockout model (Alba M et al., 2006) demonstrates normalisation of body composition in a GH-deficient context, but that model cannot be extrapolated to GH-sufficient adults. Long-term safety data beyond 49 days of dosing is also absent from the published literature, leaving questions about chronic effects on the GH/IGF-I axis, glucose regulation, and somatotroph behaviour unanswered.
Limitation 3: All foundational MOTS-c mechanistic data is from mouse models or in vitro systems. The Lee C et al. (2015) and Kim SJ et al. (2019) studies — the two primary mechanistic pillars for MOTS-c in metabolic recomposition — used diet-induced obese and aged mice. The in vitro nuclear translocation finding (Kim KH et al., 2018) used cell culture under glucose restriction. The only human data is a preliminary correlational study of 20 physically active adults (Domin R et al., 2023, PMID: 37834399), which is explicitly described as preliminary by its authors, used only 3 female participants, and cannot support causal inference. There are no published Phase I or Phase II RCTs for MOTS-c in humans measuring body composition endpoints.
Limitation 4: MOTS-c oral bioavailability is uncharacterised. All preclinical MOTS-c research used injected administration. No published peer-reviewed study has established oral bioavailability, gastric stability, or effective systemic exposure from oral delivery of MOTS-c in any model. This is not a minor detail — it directly determines whether oral formulations produce any meaningful systemic MOTS-c concentrations.
Limitation 5: The combination has never been studied. This cannot be overstated. No peer-reviewed research has examined CJC-1295, Tesamorelin, and MOTS-c in combination. The compounds in this stack have been studied individually for their respective mechanisms. The combination is not yet studied directly in peer-reviewed literature. Synergistic claims — that the GH axis modulation from CJC-1295 and Tesamorelin would compound the AMPK-mediated skeletal muscle effects of MOTS-c — remain theoretical extrapolations from independent mechanistic data, not empirical findings.
Limitation 6: Lean mass effects of Tesamorelin are context-dependent. The +1.42 kg lean mass increase in the 2026 meta-analysis (Badran AS et al., 2026, PMID: 41545261) occurred in subjects with active lipodystrophy and significant baseline VAT. Whether lean mass accrual would occur — or persist — in subjects without excess visceral adiposity is unknown.
These limitations do not negate the mechanistic rationale. They define its boundaries. The research community should be transparent about where the data ends and the hypothesis begins.
The Recomp Stack brings together three research compounds with non-overlapping mechanistic rationale: CJC-1295 for sustained pituitary-driven GH axis amplification, Tesamorelin for visceral-selective lipolysis with the strongest GHRH clinical dataset in existence, and MOTS-c for mitochondria-driven AMPK activation in skeletal muscle. The data supporting each individually — at the mechanistic and in some cases clinical level — is genuinely rigorous. The data supporting their combination is, at this point, absent.
For research contexts interested in body recomposition, the mechanistic framing here provides a grounded starting point. CJC-1295’s albumin bioconjugation extends GH axis engagement across a dosing window that no short-acting GHRH analog can match. Tesamorelin’s visceral selectivity — confirmed across multiple RCT cohorts including 806 subjects in the Phase III pooled analysis — represents one of the better-evidenced VAT-reduction mechanisms in the preclinical literature. MOTS-c’s declining serum levels with age, its correlation with muscle mass in the Domin et al. human data, and its retrograde mitonuclear signalling mechanism suggest it occupies a biological niche that GH axis compounds simply do not address.
Browse the Research Compound Catalogue for full compound specifications. Related GH axis modulation data is covered in our Research Notes. For researchers interested in metabolic compounds more broadly, see the Metabolic Compounds and Longevity Compounds sections. Researchers exploring complementary tissue repair mechanisms may also find the Wolverine Stack and Hallmarks Stack data relevant.
This post was researched and written by the BIOHACKER research editorial team. All compounds referenced in the Recomp Stack — CJC-1295, Tesamorelin, and MOTS-c — are sourced from manufacturers operating under ISO-compliant quality systems and verified via third-party HPLC purity analysis and mass spectrometry. Certificates of Analysis (COA) are available for every batch. We do not list compounds without documented purity verification. Our sourcing standards and testing methodology are detailed on the About page. All compounds are sold strictly as research compounds for laboratory use.
For research use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.